Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort.

Chalouni M, Sogni P, Miailhes P, Lacombe K, Poizot-Martin I, Chas J, Vittecoq D, Neau D, Aumaitre H, Alric L, Piroth L, Bouchaud O, Katlama C, Morlat P, Lascoux-Combe C, Gervais A, Naqvi A, Rosenthal E, Garipuy D, Barange K, Esterle L, Salmon D, Wittkop L; ANRS CO13 HEPAVIH study group.

Eur J Gastroenterol Hepatol. 2019 Apr 25. doi: 10.1097/MEG.0000000000001408. [Epub ahead of print]

PMID:
31033848
2.

Expanding the spectrum of HIV-associated myopathy.

Landon-Cardinal O, Gallay L, Dubourg O, Maisonobe T, Léonard-Louis S, Beniken D, Simon A, Behin A, Stojkovic T, Duyckaerts C, Breton G, Rigolet A, Fain O, Meyohas MC, Leport C, Valantin MA, Vittecoq D, Bergmann JF, Hanslik T, Chauveheid MP, Amoura Z, de Broucker T, Eymard B, Beaudequin N, Benveniste O, Allenbach Y.

J Neurol Neurosurg Psychiatry. 2019 Apr 11. pii: jnnp-2018-319419. doi: 10.1136/jnnp-2018-319419. [Epub ahead of print] No abstract available.

PMID:
30975823
3.

Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.

Shili-Masmoudi S, Sogni P, de Ledinghen V, Esterle L, Valantin MA, Poizot-Martin I, Simon A, Rosenthal E, Lacombe K, Pialoux G, Bouchaud O, Gervais-Hasenknoff A, Goujard C, Piroth L, Zucman D, Dominguez S, Raffi F, Alric L, Bani-Sadr F, Lascoux-Combe C, Garipuy D, Miailhes P, Vittecoq D, Duvivier C, Aumaître H, Neau D, Morlat P, Dabis F, Salmon D, Wittkop L; ANRS CO13 HEPAVIH study group.

PLoS One. 2019 Jan 25;14(1):e0211286. doi: 10.1371/journal.pone.0211286. eCollection 2019.

4.

Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort.

Billa O, Chalouni M, Salmon D, Poizot-Martin I, Gilbert C, Katlama C, Neau D, Chas J, Morlat P, Lacombe K, Naqvi A, Barange K, Gervais A, Bouchaud O, Rosenthal E, Lascoux-Combe C, Garipuy D, Alric L, Dominguez S, Vittecoq D, Goujard C, Duvivier C, Aumaitre H, Miailhes P, Zucman D, Simon A, Lazaro E, Raffi F, Esterle L, Wittkop L, Bani-Sadr F; ANRS CO13 HEPAVIH Study Group.

PLoS One. 2018 Dec 18;13(12):e0208657. doi: 10.1371/journal.pone.0208657. eCollection 2018.

5.

Clearance of carbapenem-resistant Enterobacteriaceae vs vancomycin-resistant enterococci carriage after faecal microbiota transplant: a prospective comparative study.

Dinh A, Fessi H, Duran C, Batista R, Michelon H, Bouchand F, Lepeule R, Vittecoq D, Escaut L, Sobhani I, Lawrence C, Chast F, Ronco P, Davido B.

J Hosp Infect. 2018 Aug;99(4):481-486. doi: 10.1016/j.jhin.2018.02.018. Epub 2018 Mar 2.

PMID:
29477634
6.

Hospitalization of HIV positive patients: Significant demand affecting all hospital sectors.

Seng R, Mutuon P, Riou J, Duvivier C, Weiss L, Lelievre JD, Meyer L, Vittecoq D, Zak Dit Zbar O, Frenkiel J, Frank-Soltysiak M, Boue F, Rapp C, Sobel A, Brucker G, Goujard C, Salmon D; COREVIH.

Rev Epidemiol Sante Publique. 2018 Feb;66(1):7-17. doi: 10.1016/j.respe.2017.08.002. Epub 2017 Dec 10.

PMID:
29233572
7.

Short article: Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH).

Marcellin F, Protopopescu C, Esterle L, Wittkop L, Piroth L, Aumaitre H, Bouchaud O, Goujard C, Vittecoq D, Dabis F, Salmon-Ceron D, Spire B, Roux P, Carrieri MP; ANRS CO13-HEPAVIH Study Group.

Eur J Gastroenterol Hepatol. 2017 Jul;29(7):786-791. doi: 10.1097/MEG.0000000000000883.

PMID:
28418984
8.

Is faecal microbiota transplantation an option to eradicate highly drug-resistant enteric bacteria carriage?

Davido B, Batista R, Michelon H, Lepainteur M, Bouchand F, Lepeule R, Salomon J, Vittecoq D, Duran C, Escaut L, Sobhani I, Paul M, Lawrence C, Perronne C, Chast F, Dinh A.

J Hosp Infect. 2017 Apr;95(4):433-437. doi: 10.1016/j.jhin.2017.02.001. Epub 2017 Feb 6.

PMID:
28237504
9.

Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.

Piroth L, Wittkop L, Lacombe K, Rosenthal E, Gilbert C, Miailhes P, Carrieri P, Chas J, Poizot-Martin I, Gervais A, Dominguez S, Neau D, Zucman D, Billaud E, Morlat P, Aumaitre H, Lascoux-Combe C, Simon A, Bouchaud O, Teicher E, Bani-Sadr F, Alric L, Vittecoq D, Boué F, Duvivier C, Valantin MA, Esterle L, Dabis F, Sogni P, Salmon D; ANRS CO13 HEPAVIH study group.

J Hepatol. 2017 Jul;67(1):23-31. doi: 10.1016/j.jhep.2017.02.012. Epub 2017 Feb 22.

PMID:
28235612
10.

Amoxicillin-clavulanic acid prescriptions at the Greater Paris University Hospitals (AP-HP).

Fusier I, Parent de Curzon O, Touratier S, Escaut L, Lafaurie M, Fournier S, Sinègre M, Lechat P, Vittecoq D; Anti-Infective Drug Committee (COMAI) of the public hospital system of the city of Paris (AP–HP).

Med Mal Infect. 2017 Feb;47(1):42-49. doi: 10.1016/j.medmal.2016.09.003. Epub 2016 Oct 17.

PMID:
27765474
11.

First Occurrence of OXA-72-Producing Acinetobacter baumannii in Serbia.

Dortet L, Bonnin RA, Bernabeu S, Escaut L, Vittecoq D, Girlich D, Imanci D, Fortineau N, Naas T.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5724-30. doi: 10.1128/AAC.01016-16. Print 2016 Oct.

12.

All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.

Sogni P, Gilbert C, Lacombe K, Piroth L, Rosenthal E, Miailhes P, Gervais A, Esterle L, Chas J, Poizot-Martin I, Dominguez S, Simon A, Morlat P, Neau D, Zucman D, Bouchaud O, Lascoux-Combe C, Bani-Sadr F, Alric L, Goujard C, Vittecoq D, Billaud E, Aumaître H, Boué F, Valantin MA, Dabis F, Salmon D, Wittkop L.

Clin Infect Dis. 2016 Sep 15;63(6):763-770. doi: 10.1093/cid/ciw379. Epub 2016 Jun 17.

PMID:
27317796
13.

Intention to vaccinate against influenza among health care workers caring for immunocompromised patients.

Loulergue P, Kernéis S, Stern JB, Kassis-Chikani N, Derradji O, Escaut L, Launay O, Vittecoq D, Wyplosz B.

Am J Infect Control. 2016 Sep 1;44(9):1080-2. doi: 10.1016/j.ajic.2016.02.030. Epub 2016 Apr 22. No abstract available.

PMID:
27112367
14.

Infectious complications after liver transplantation in human immunodeficiency virus-infected recipients.

Teicher E, Boufassa F, Vittecoq D, Antonini TM, Tateo MG, Coilly A, Roque-Afonso AM, Kassis-Chikhani N, Lambotte O, Ichai P, Samuel D, Duclos-Vallee JC.

Transpl Infect Dis. 2015 Oct;17(5):662-70. doi: 10.1111/tid.12422. Epub 2015 Sep 26.

PMID:
26192379
15.

High Rate of Acquisition but Short Duration of Carriage of Multidrug-Resistant Enterobacteriaceae After Travel to the Tropics.

Ruppé E, Armand-Lefèvre L, Estellat C, Consigny PH, El Mniai A, Boussadia Y, Goujon C, Ralaimazava P, Campa P, Girard PM, Wyplosz B, Vittecoq D, Bouchaud O, Le Loup G, Pialoux G, Perrier M, Wieder I, Moussa N, Esposito-Farèse M, Hoffmann I, Coignard B, Lucet JC, Andremont A, Matheron S.

Clin Infect Dis. 2015 Aug 15;61(4):593-600. doi: 10.1093/cid/civ333. Epub 2015 Apr 22.

PMID:
25904368
16.

Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.

Wyplosz B, Derradji O, Hong E, François H, Durrbach A, Duclos-Vallée JC, Samuel D, Escaut L, Launay O, Vittecoq D, Taha MK.

Transpl Infect Dis. 2015 Apr;17(2):322-7. doi: 10.1111/tid.12359. Epub 2015 Mar 6.

17.

Photo quiz. Dyspnea and fever in an allogeneic stem cell recipient.

Angoulvant A, Stern JB, Wittnebel S, Bourhis JH, Gachot B, Vittecoq D, Wyplosz B.

Clin Infect Dis. 2015 Jan 1;60(1):100, 157-8. doi: 10.1093/cid/ciu839. No abstract available.

PMID:
25504499
18.

Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.

Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebagh M, Coilly A, Bonhomme-Faivre L, Roque-Afonso AM, Vittecoq D, Samuel D, Taburet AM, Duclos-Vallée JC.

AIDS. 2015 Jan 2;29(1):53-8. doi: 10.1097/QAD.0000000000000516.

PMID:
25387314
19.

Care of hepatitis C virus infection in France: modifications in three consecutive surveys between 1995 and 2010.

Geri G, Maynard M, Rosenthal E, Fontaine H, Lacombe K, Slama L, Goujard C, Loustaud-Ratti V, Bergmann JF, Morlat P, Vittecoq D, Alric L, Cacoub P; GERMIVIC Group.

Liver Int. 2014 Oct;34(9):1349-57.

PMID:
25368876
20.

Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.

Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevaliez S, Aboulker JP, Molina JM; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group.

Clin Infect Dis. 2014 Dec 15;59(12):1768-76. doi: 10.1093/cid/ciu659. Epub 2014 Aug 18.

PMID:
25139963
21.

PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.

Saadoun D, Resche Rigon M, Pol S, Thibault V, Blanc F, Pialoux G, Karras A, Bazin-Kara D, Cazorla C, Vittecoq D, Musset L, Peltier J, Decaux O, Ziza JM, Lambotte O, Cacoub P.

J Hepatol. 2015 Jan;62(1):24-30. doi: 10.1016/j.jhep.2014.08.015. Epub 2014 Aug 15.

PMID:
25135864
22.

Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.

Barau C, Braun J, Vincent C, Haim-Boukobza S, Molina JM, Miailhes P, Fournier I, Aboulker JP, Vittecoq D, Duclos-Vallée JC, Taburet AM, Teicher E; Agence Nationale de Recherche sur le Sida et les hépatites (ANRS) 148 Study Group.

Clin Infect Dis. 2014 Oct 15;59(8):1177-84. doi: 10.1093/cid/ciu515. Epub 2014 Jul 3.

PMID:
24992955
23.

Acquisition of carbapenemase-producing Enterobacteriaceae by healthy travellers to India, France, February 2012 to March 2013.

Ruppé E, Armand-Lefèvre L, Estellat C, El-Mniai A, Boussadia Y, Consigny PH, Girard PM, Vittecoq D, Bouchaud O, Pialoux G, Esposito-Farèse M, Coignard B, Lucet JC, Andremont A, Matheron S.

Euro Surveill. 2014 Apr 10;19(14). pii: 20768.

24.

Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft.

Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebagh M, Coilly A, Bonhomme-Faivre L, Peytavin G, Roque-Afonso AM, Vittecoq D, Samuel D, Taburet AM, Duclos-Vallée JC.

AIDS. 2013 Oct 23;27(16):2655-7. doi: 10.1097/01.aids.0000432539.77711.f4.

PMID:
23939241
25.

Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.

Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combe C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L; ANRS PRIMO and COPANA Cohorts.

PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. Print 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/aed12a66-9c76-4e49-806b-881a2fe23bba. Goujard, Cecile [added].

26.

Persistence of yellow fever vaccine-induced antibodies after solid organ transplantation.

Wyplosz B, Burdet C, François H, Durrbach A, Duclos-Vallée JC, Mamzer-Bruneel MF, Poujol P, Launay O, Samuel D, Vittecoq D, Consigny PH; GEVACCIM.

Am J Transplant. 2013 Sep;13(9):2458-61. doi: 10.1111/ajt.12338. Epub 2013 Jul 8.

27.

Eradication of an outbreak of vancomycin-resistant Enterococcus (VRE): the cost of a failure in the systematic screening.

Escaut L, Bouam S, Frank-Soltysiak M, Rudant E, Saliba F, Kassis N, Presiozi P, Vittecoq D.

Antimicrob Resist Infect Control. 2013 Jun 6;2(1):18. doi: 10.1186/2047-2994-2-18.

28.

Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.

Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P.

Ann Rheum Dis. 2014 May;73(5):831-7. doi: 10.1136/annrheumdis-2012-202770. Epub 2013 Apr 20.

29.

[Corneal manifestations of measles in the unvaccinated adult: two typical cases during an epidemic].

M'garrech M, Gendron G, de Monchy I, Pogorzalek N, Rebaudet S, Vittecoq D, Labetoulle M.

J Fr Ophtalmol. 2013 Mar;36(3):197-201. doi: 10.1016/j.jfo.2012.02.016. Epub 2012 Nov 16. French.

30.

Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.

Loko MA, Bani-Sadr F, Valantin MA, Lascoux-Combe C, Fontaine H, Bonnard P, Gervais A, Bouchaud O, Garipuy D, Quertainmont Y, Vittecoq D, Tehrani MS, Winnock M, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group.

Antivir Ther. 2012;17(7):1335-43. doi: 10.3851/IMP2419. Epub 2012 Oct 10.

PMID:
23052829
31.

Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.

Fagard C, Colin C, Charpentier C, Rami A, Jacomet C, Yeni P, Vittecoq D, Katlama C, Molina JM, Descamps D, Chêne G, Yazdanpanah Y; ANRS 139 TRIO Trial Group.

J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):489-93. doi: 10.1097/QAI.0b013e31824bb720.

PMID:
22293546
32.

Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH.

Salmon D, Bani-Sadr F, Loko MA, Stitou H, Gervais A, Durant J, Rosenthal E, Quertainmont Y, Barange K, Vittecoq D, Shoai-Tehrani M, Alvarez M, Winnock M, Trinchet JC, Dabis F, Sogni P.

J Hepatol. 2012 Apr;56(4):862-8. doi: 10.1016/j.jhep.2011.11.009. Epub 2011 Dec 13.

PMID:
22173166
33.

Generic drug prescriptions following hospital discharge: a prospective study in France.

Chu C, Rudant E, Bonvalet M, Agostini H, Cavalié P, Bonhomme-Faivre L, Frenkiel J, Taillandier J, Boissonnas A, Vittecoq D, Wyplosz B.

Eur J Intern Med. 2011 Oct;22(5):e45-9. doi: 10.1016/j.ejim.2011.01.016. Epub 2011 Mar 15.

PMID:
21925042
34.

Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation.

Antonini TM, Sebagh M, Roque-Afonso AM, Teicher E, Roche B, Sobesky R, Coilly A, Vaghefi P, Adam R, Vittecoq D, Castaing D, Samuel D, Duclos-Vallée JC.

Am J Transplant. 2011 Aug;11(8):1686-95. doi: 10.1111/j.1600-6143.2011.03608.x. Epub 2011 Jul 12.

35.

[Infections at risk for epidemic or biological threat. Importance of the initial management of suspect patients].

Leport C, Vittecoq D, Perronne C, Debord T, Carli P, Camphin P, Bricaire F; Comité de pilotage de la coordination des urgences infectieuses et du risque épidémique et biologique (CO REB) en île-de-France.

Presse Med. 2011 Apr;40(4 Pt 1):336-40. doi: 10.1016/j.lpm.2010.10.033. Epub 2011 Jan 21. French. No abstract available.

PMID:
21256694
36.

The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.

Loko MA, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, Gillet S, Pambrun E, Delaune J, Valantin MA, Poizot-Martin I, Neau D, Bonnard P, Rosenthal E, Barange K, Morlat P, Lacombe K, Gervais A, Rouges F, See AB, Lascoux-Combe C, Vittecoq D, Goujard C, Duvivier C, Spire B, Izopet J, Sogni P, Serfaty L, Benhamou Y, Bani-Sadr F, Dabis F; ANRS CO 13 HEPAVIH Study Group.

BMC Infect Dis. 2010 Oct 22;10:303. doi: 10.1186/1471-2334-10-303.

37.

Probable intrafamily transmission of a highly virulent CTX-M-3-producing Escherichia coli belonging to the emerging phylogenetic subgroup D2 O102-ST405 clone.

Mihaila L, Wyplosz B, Clermont O, Garry L, Hipeaux MC, Vittecoq D, Dussaix E, Denamur E, Branger C.

J Antimicrob Chemother. 2010 Jul;65(7):1537-9. doi: 10.1093/jac/dkq155. Epub 2010 May 13. No abstract available.

PMID:
20466852
38.

Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.

Gatell JM, Katlama C, Grinsztejn B, Eron JJ, Lazzarin A, Vittecoq D, Gonzalez CJ, Danovich RM, Wan H, Zhao J, Meibohm AR, Strohmaier KM, Harvey CM, Isaacs RD, Nguyen BY; Protocol 005 Team.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):456-63.

39.

Save antibiotics. What can be done to prevent a forecasted disaster! Suggestions to promote the development of new antibiotics.

Trémolières F, Cohen R, Gauzit R, Vittecoq D, Stahl JP.

Med Mal Infect. 2010 Mar;40(3):129-34. doi: 10.1016/j.medmal.2010.01.007. Epub 2010 Feb 12.

PMID:
20153591
40.

Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial.

Bouldouyre MA, Charreau I, Marchou B, Tangre P, Katlama C, Morlat P, Meiffredy V, Vittecoq D, Bierling P, Aboulker JP, Molina JM; ANRS 106 Study Group.

J Acquir Immune Defic Syndr. 2009 Dec;52(5):531-7. doi: 10.1097/QAI.0b013e3181be73e3.

PMID:
19855285
41.

Preservation of immune function and anti-hepatitis C virus (HCV) immune responses after liver transplantation in HIV-HCV coinfected patients (ANRS-HC08 "THEVIC" trial).

Samri A, Roque-Afonso AM, Beran O, Tateo M, Teicher E, Feray C, Sebagh M, Guettier C, Dussaix E, Vittecoq D, Samuel D, Autran B, Duclos-Vallée JC.

J Hepatol. 2009 Dec;51(6):1000-9. doi: 10.1016/j.jhep.2009.06.031. Epub 2009 Sep 12.

PMID:
19833404
42.

Enfuvirtide: a safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation.

Teicher E, Abbara C, Duclos-Vallée JC, Antonini T, Bonhomme-Faivre L, Desbois D, Samuel D, Vittecoq D.

Liver Transpl. 2009 Oct;15(10):1336-42. doi: 10.1002/lt.21818.

43.

Cerebrovascular diseases in HIV-infected patients.

Monsuez JJ, Goujon C, Wyplosz B, Couzigou C, Escaut L, Vittecoq D.

Curr HIV Res. 2009 Sep;7(5):475-80. Review.

PMID:
19534663
44.

Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs.

Tricot L, Teicher E, Peytavin G, Zucman D, Conti F, Calmus Y, Barrou B, Duvivier C, Fontaine C, Welker Y, Billy C, de Truchis P, Delahousse M, Vittecoq D, Salmon-Céron D.

Am J Transplant. 2009 Aug;9(8):1946-52. doi: 10.1111/j.1600-6143.2009.02684.x. Epub 2009 Jun 10.

45.

[Therapeutic education of the patient infected with HIV].

Derradji O, Escaut L, Couzigou C, Fischer S, Esnault M, Colombatto C, Isola M, Vittecoq D.

Soins. 2009 Apr;(734):40-2. French. No abstract available.

PMID:
19475827
46.

Relationship between polymerase gamma (POLG) polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients: a case-control study.

Chiappini F, Teicher E, Saffroy R, Debuire B, Vittecoq D, Lemoine A.

Curr HIV Res. 2009 Mar;7(2):244-53.

PMID:
19275594
47.

Efficacy of etravirine for treatment of acute HIV meningoencephalitis.

Couzigou C, Seang S, Morand-Joubert L, Roque-Afonso AM, Escaut L, Vittecoq D.

Clin Infect Dis. 2009 Mar 15;48(6):e62-5. doi: 10.1086/597109.

PMID:
19193114
48.

HIV-associated vascular diseases: structural and functional changes, clinical implications.

Monsuez JJ, Charniot JC, Escaut L, Teicher E, Wyplosz B, Couzigou C, Vignat N, Vittecoq D.

Int J Cardiol. 2009 Apr 17;133(3):293-306. doi: 10.1016/j.ijcard.2008.11.113. Epub 2009 Jan 7. Review.

PMID:
19131130
49.

[Vaccinations for the traveling adult solid organ transplant recipient (excluding hematopoietic stem cell transplant recipients)].

Wyplosz B, Van der Vliet D, Consigny PH, Calmus Y, Mamzer-Bruneel MF, Guillemain R, Malvy D, Samuel D, Vittecoq D, Launay O; pour le groupe d'étude de la vaccination des immunodéprimés (GEVACCIM).

Med Mal Infect. 2009 Apr;39(4):225-33. doi: 10.1016/j.medmal.2008.11.006. Epub 2008 Dec 25. Review. French.

PMID:
19111416
50.

[A woman (French), Nobel prize for medicine].

Vittecoq D, Françoise M.

Med Mal Infect. 2008 Nov;38(11):563. doi: 10.1016/j.medmal.2008.10.012. French. No abstract available.

PMID:
19041526

Supplemental Content

Loading ...
Support Center